Zealand Pharma Signs Licensing Agreement With Abbott Laboratories for the Further Clinical Development and Commercialization of AP214 (ZP1480) for Prevention of Acute Kidney Injury

Published: May 03, 2012

COPENHAGEN, May 3, 2012 (GLOBE NEWSWIRE) -- Zealand Pharma A/S (Copenhagen:ZEAL), a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, announces that a license agreement has been signed with Abbott for the further development and commercialization of AP214 (referred to as ZP1480 by Zealand Pharma). AP214 (ZP1480) is a first-in-class melanocortin peptide agonist, invented and developed by Action Pharma A/S, and modified by using Zealand Pharma's SIPĀ®-technology.

Back to news